The meta-analysis showed that there was no significant difference in LBM between those treated with GLP-1 RA and the control group (MD = 4.61, [-4.19
Insurance Verification: Automates checking eligibility, benefits, and plan requirements for GLP-1 medications, ensuring aligned submissions and reducing denials
Possible mild side effects include injection site irritation, headaches, or flushing
Granules India's April 2025 acquisition of Senn Chemicals (Switzerland) a deal that signals Indian companies targeting European peptide CDMO capabilities validates the strategic direction that Piramal has been pursuing organically
22 As a result, tirzepatide is currently the lead weight loss drug, with new therapies aiming to surpass tirzepatide, or match its efficacy, alongside a more favourable dosing strategy and/or side effect profile